4-(三氟甲氧基)苄基硫醇 | 175278-03-2

• 物质功能分类: 化学试剂 - 有机试剂 - 硫醇盐
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 4-(三氟甲氧基)苄基硫醇
• 中文别名: 4-三氟甲氧基苯基甲硫醇
• 英文名称: 4-(trifluoromethoxy)benzylmercaptan
• 英文别名: [4-(Trifluoromethoxy)phenyl]methanethiol
• CAS: 175278-03-2
• 化学式: C₈H₇F₃OS
• 分子量: 208.204
• InChiKey: VWLQXXSOXQNHJM-UHFFFAOYSA-N

物化性质

• 沸点：
  89 °C
• 密度：
  1.299±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  10.2
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R20/21/22
• 海关编码：
  2930909090

SDS

Name:	[4-(Trifluoromethoxy)phenyl]methanethiol 95+% Material Safety Data Sheet
Synonym:
CAS:	175278-03-2

Section 1 - Chemical Product MSDS Name:[4-(Trifluoromethoxy)phenyl]methanethiol 95+% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
175278-03-2	[4-(Trifluoromethoxy)phenyl]methanethi	95+%	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.Moisture sensitive.Air sensitive.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. May cause respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Store under nitrogen.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 175278-03-2: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: colorless
Odor: stench
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 93 - 95 deg C @15mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H7F3OS
Molecular Weight: 208

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials, moisture, exposure to air, contact with water.
Incompatibilities with Other Materials:
Acids, bases, oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, oxides of sulfur, carbon dioxide, fluorine, hydrogen fluoride gas.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 175278-03-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
[4-(Trifluoromethoxy)phenyl]methanethiol - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC LIQUID, ORGANIC, N.O.S.*
Hazard Class: 6.1
UN Number: 2810
Packing Group: III
IMO
Shipping Name: TOXIC LIQUID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2810
Packing Group: III
RID/ADR
Shipping Name: TOXIC LIQUID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2810
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
Safety Phrases:
S 36/37 Wear suitable protective clothing and
gloves.
WGK (Water Danger/Protection)
CAS# 175278-03-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 175278-03-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 175278-03-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(三氟甲氧基)苄基硫醇 在 甲醇 、 2,2'-联吡啶 、 O-新戊酰羟铵三氟甲磺酸盐 、 iron(II) chloride 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 以84%的产率得到(4-(trifluoromethoxy)phenyl)methanesulfinamide
  参考文献：
  名称：

  羟胺衍生试剂作为双氧化剂和氨基供体，用于铁催化从硫醇制备未保护的亚磺酰胺。

  摘要：

  开发了一种铁催化反应，通过直接转移-O和游离-NH 2基团，将硫醇（-SH）选择性转化为亚磺酰胺（-SONH 2 ）。该反应使用工作台稳定的羟胺衍生试剂在温和条件下进行，表现出广泛的官能团耐受性，可扩展且无需使用任何贵金属催化剂或额外的氧化剂即可进行。这种新颖、实用的反应可一步形成两个不同的新键（S=O 和 S−N），从而化学选择性地形成有价值的、未受保护的亚磺酰胺产物。初步的机理研究表明醇溶剂作为氧原子供体的作用。

  DOI：

  10.1002/anie.202011138

文献信息

• Inhibitors of c-Jun N-terminal kinases
  申请人：Liu Gang

  公开号：US20060173050A1

  公开（公告）日：2006-08-03

  The present invention relates to compounds that are inhibitors of c-jun N-terminal kinase 1, 2, or 3 (JNK1, JNK2, or JNK3), compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by the activation of JNK1, JNK2 and JNK3.

  本发明涉及作为c-jun N-末端激酶1、2或3（JNK1、JNK2或JNK3）抑制剂的化合物，包含这些化合物的组合物以及这些化合物在预防或治疗由JNK1、JNK2和JNK3激活调控的疾病中的用途。
• Novel lincomycin derivatives possessing antimicrobial activity
  申请人：Lewis G. Jason

  公开号：US20050043248A1

  公开（公告）日：2005-02-24

  Novel lincomycin derivatives are disclosed. These lincomycin derivatives exhibit antibacterial activity. The compounds of the subject invention may exhibit potent activities against bacteria, including gram positive organisms, and may be useful antimicrobial agents. Methods of synthesis and of use of the compounds are also disclosed.

  新型的林可霉素衍生物被披露。这些林可霉素衍生物表现出抗菌活性。本发明的化合物可能对细菌，包括革兰氏阳性生物，表现出强效活性，并且可能是有用的抗微生物药剂。该化合物的合成和使用方法也被披露。
• Novel lincomycin derivatives possessing antibacterial activity
  申请人：Lewis G. Jason

  公开号：US20050215488A1

  公开（公告）日：2005-09-29

  Novel lincomycin derivatives are disclosed. These lincomycin derivatives exhibit antibacterial activity. The compounds of the subject invention may exhibit potent activities against bacteria, including Gram positive organisms, and may be useful antimicrobial agents. Methods of synthesis and of use of the compounds are also disclosed.

  新型的林可霉素衍生物已被披露。这些林可霉素衍生物表现出抗菌活性。本发明的化合物可能对细菌，包括革兰氏阳性生物，表现出强效活性，并可能是有用的抗微生物药剂。该化合物的合成和使用方法也已被披露。
• Use of azacyclic or azabicyclic pyrazine compounds for treating anxiety
  申请人：ELI LILLY AND COMPANY

  公开号：EP0773027A1

  公开（公告）日：1997-05-14

  The present invention relates a method for treating anxiety using azacyclic and azabicyclic pyrazine compounds.

  这项发明涉及一种使用氮杂环和氮杂双环吡嗪化合物治疗焦虑的方法。
• Pyrimidine derivatives as ghrelin receptor modulators
  申请人：Kosogof Christi

  公开号：US20050070712A1

  公开（公告）日：2005-03-31

  The present invention is related to compounds of formula (I), or a therapeutically suitable salt or prodrug thereof, the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by ghrelin including anorexia, cancer cachexia, eating disorders, age-related decline in body composition, weight gain, obesity, and diabetes mellitus.

  本发明涉及式(I)的化合物，或者其治疗上适宜的盐或前药，该化合物的制备、含有该化合物的组合物以及在预防或治疗由生长激素释放素调节的疾病中使用该化合物，包括厌食症、癌症恶病质、进食障碍、与年龄相关的身体组成下降、体重增加、肥胖和糖尿病。